pharmaphorum| News & views on pharma and biotech’s evolving future

News

Anthropic puts life sciences at heart of new AI model

Anthropic has released Claude Fable 5, trumpeting its R&D credentials, but has faced a backlash over "safeguards" built into the model.

News

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

Market Access

The expanding role of early-phase trials in modern drug deve...

Oncology

Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Digital

The pulse of progress: AI, real-world data, and the ethics o...

What kind of data should train and power the next generation of healthcare AI?

Featured Content

Oncology

Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Spotlight on

ASCO 2026

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Patients

pharmaphorum podcast Episode 263, Rebecca Guntern - Sandoz

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Oncology

Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Anthropic puts life sciences at heart of new AI model

Anthropic has released Claude Fable 5, trumpeting its R&D credentials, but has faced a backlash over "safeguards" built into the model.

News

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

News

Lilly wins new FDA approval for eczema drug Ebglyss

Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.

News

Bayer's asundexian starts EU review for ischaemic stroke

The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

Views & Analysis

Oncology

Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Digital

The pulse of progress: AI, real-world data, and the ethics o...

What kind of data should train and power the next generation of healthcare AI?

Patients

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Oncology

prostate cancer microscopic image of adenocarcinoma

After Pluvicto: Alpha radiopharma and prostate cancer

Dr Philip Kantoff, a world-renowned prostate cancer clinician and researcher, discusses alpha radiopharma treatment possibilities.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Oncology

Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Patients

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Oncology

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Partner Content

Press Releases

Partner Content

Inizio Launches Intelligent Congress to Turn Event Investmen...

Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress

Event

Partner Content

17th World ADC San Diego | October 12-15, 2026

The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes

Event

Partner Content

6th Rare & Genetic Kidney Disease Drug Development Summit

The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc

Press Releases

Partner Content

Navigating Change: Key Industry Insights at PHARMAP 2026

PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content